journal article·2006-10

Synthesis of TiO2 nanostructured reservoir with temozolomide: Structural evolution of the occluded drug

T. López, J. Sotelo, J. Navarrete, J.A. Ascencio

Optical Materials· Volume 29· Issue 1
Publisher page

Abstract

Sol–gel synthesized nanostructured TiO2 matrix were produced with different channel sizes, where drug are immersed, producing a reservoir with Temozolomide (TMZ). This drug is particularly important for the treatment of cancer tumors, which are fundamentally a consequence of the uncontrolled reproduction of human cell. In this way the chemotherapy plays an important role in the treatment of both recurrent and newly diagnosed patients. In the handling of brain tumors TMZ has been discovered as a recent and efficient second generation drug employed in the control of advanced brain gliomas, and it is a welcome addition. Its active component binds to the cancerous DNA cells, thus preventing their disordered growth, destroying them. In this work, we report the synthesis of TiO2 nanostructured reservoir with TMZ, focusing the effort to the understanding of structural effects on the TMZ configuration by using nuclear magnetic resonance, Raman and IR spectroscopy methods. Our results establish that TMZ molecules are quite sensible to chemical processes and it produces the activation of the molecule, which is followed and understood with help of quantum molecular simulation methods. The study of the molecules allows determining the conditions that produce the activation and chemical selectivity of the molecules, which determines the conditions of synthesis. This information gives parameters for the reservoir structural and chemical optimization.
Source: openaire · Quality: candidate unverified · Source record ↗

Research context

OpenAlex topics: Innovative Microfluidic and Catalytic Techniques Innovation · Catalytic Processes in Materials Science · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (23)

Show source-provided references
1. Ascencio · J. Phys. Chem. B · 2005 · 109 · 880610.1021/jp0460083 ↗
2. T. Lopez, J. Navarrete, R. Conde, J. Manjarrez, R.D.R.D. Gonzalez, J. Biom. Mat. Res.: Part A., in press.
3. Lopez · Opt. Mat. · 2005 · 27 · 127010.1016/j.optmat.2004.11.023 ↗
4. Tuszynski · Lanc. Neurol. · 2002 · 1 · 5110.1016/S1474-4422(02)00006-6 ↗
5. OReilly · Eur. J. Cancer · 1993 · 29 · 94010.1016/S0959-8049(05)80198-4 ↗
6. Newlands · Eur. J. Cancer. · 1996 · 32A · 223610.1016/S0959-8049(96)00258-4 ↗
7. Bower · Cancer Chemot. Pharm. · 1997 · 40 · 48410.1007/s002800050691 ↗
8. Yung · J. Clin. Oncol. · 1999 · 17 · 276210.1200/JCO.1999.17.9.2762 ↗
9. Newlands · Br. J. Cancer · 1992 · 65 · 28710.1038/bjc.1992.57 ↗
10. Bleehen · J. Clin. Oncol. · 1995 · 13 · 91010.1200/JCO.1995.13.4.910 ↗
11. Middleton · Br. J. Cancer · 1998 · 78 · 119910.1038/bjc.1998.654 ↗
12. Stevens · J. Med. Chem. · 1984 · 27 · 19610.1021/jm00368a016 ↗
13. Sanjiv · The Oncologist · 2000 · 5 · 14410.1634/theoncologist.5-2-144 ↗
14. Patel · Proc. Am. Soc. Clin. Oncol. · 1995 · 14 · 461a10.1016/j.soc.2005.04.003 ↗
15. Hamad · J. Phys. Chem. B · 2005 · 109 · 1574110.1021/jp0521914 ↗
16. Ramírez · J. Coord. Chem. · 2000 · 50 · 110.1080/00958970008054920 ↗
17. Garcia-Salinas · Nuc. Med. Biol. · 2001 · 28 · 31910.1016/S0969-8051(00)00174-8 ↗
18. Delley · J. Chem. Phys. · 2000 · 113 · 775610.1063/1.1316015 ↗
19. Perdew · Phys. Rev. B · 1992 · 45 · 1324410.1103/PhysRevB.45.13244 ↗
20. Pearson · J. Am. Chem. Soc. · 1998 · 110 · 209210.1021/ja00215a013 ↗
21. Ascencio-Gutiérrez · Afinidad · 2000 · 487 · 180
22. Torres-García · Appl. Phys. A · 2004 · 79 · 203710.1007/s00339-004-2668-0 ↗
23. Rosquete-Pina · Appl. Phys. A · 2004 · 79 · 191310.1007/s00339-004-2740-9 ↗